---
layout: default
---

---

<h3 style="text-align:center">ANNOUNCEMENT</h3>
<h4 style="text-align:center">Certara Acquires Integrated Nonclinical Development Solutions</h4>
<p style="font-style:italic; text-align:center">Expands software portfolio and nonclinical drug development expertise</p>

<p>Certara, Inc., a global leader in biosimulation, announced on January 5, 2022 the acquisition of Integrated Nonclinical Development Solutions, Inc. (INDS), a company that provides the SEND Explorer® software and drug development consulting with a focus on nonclinical and toxicology support.</p>

<p>"We are thrilled to join Certara and be part of a bigger future together," said James R. Herman, President of INDS.  "This is a great fit on multiple levels – technology, talent and mission to accelerate medicines.  We are enthusiastic about the opportunities this combination presents for INDS and our clients."</p>

<p style="font-weight:bold">About Certara</p>

<p>Certara accelerates medicines using proprietary biosimulation software and technology to transform traditional drug discovery and development. Its clients include 1,650 global biopharmaceutical companies, leading academic institutions, and key regulatory agencies across 61 countries.
More information about the acquisition may be found <a href="https://www.certara.com/resources/?categories=pressrelease&&categories2=announcement">here</a>.</p>


### The INDS Advantage

The specialized, complementary expertise of our team members enables INDS to
provide you drug development support from target selection to product
registration. Our data management and information technology specialists work
closely with our toxicologists to deliver software solutions that truly reflect
end-user needs for ease-of-use and flexibility. Our team consists of board
certified toxicologists, veterinarians, and information technology and business
operations experts with more than 100 years of combined experience in the
pharmaceutical and contract research industries.

### Our Experience

-   Advancing over 120 compounds in all major therapeutic areas to clinical
    trials, using both traditional and alternative paradigms, including filing
    industry's first exploratory IND.
-   Advancing compounds to market, including several first-in-class drugs
    (Cognex®, ReZulin®, Neurontin®, LYRICA®) and the world's best selling drug
    Lipitor®, through design and execution of standard studies and extensive
    mechanistic investigations.
-   Developing innovative informatics solutions including state-of-the-art data
    warehousing, data visualization, interpretations and automated
    reporting tools.
-   Integrating and implementing SEND 3.0.

### Committed To Your Success

Whether you lack internal safety expertise or need to supplement your internal
resources to meet peak demands, contact INDS. We have the know-how you need to
succeed.
